Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

George Abela

Cardiovascular Disease East Lansing, MI Medical Doctor

NPI 1629012299 CMS profile 118492

4660 S Hagadorn Rd Ste 600, Ste 600, East Lansing, MI 48823

Open in the dashboard

General payments

$21,809

228 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, George Abela of East Lansing, MI is reported in the CMS Open Payments database as having received $21,809 across 228 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,395 38
2024 General $1,314 38
2023 General $712 25
2022 General $1,026 28
2021 General $4,819 31
2020 General $306 11
2019 General $12,236 57

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • George Abela
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to George Abela were reported at $1,395. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year George Abela Cardiovascular Disease median Middle half National median
2019 $12,236 $450 $127–$1,392 $163
2020 $306 $242 $77–$751 $114
2021 $4,819 $335 $101–$1,037 $132
2022 $1,026 $395 $121–$1,211 $149
2023 $712 $443 $136–$1,283 $160
2024 $1,314 $450 $136–$1,323 $164
2025 $1,395 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $6,945 17 payments
  2. Kowa Pharmaceuticals America, Inc. $4,225 7 payments
  3. Amarin Pharma Inc. $3,606 2 payments
  4. Boston Scientific Corporation $1,083 26 payments
  5. Novartis Pharmaceuticals Corporation $807 41 payments
  6. Medtronic, Inc. $757 13 payments
  7. Esperion Therapeutics, Inc. $609 3 payments
  8. Janssen Pharmaceuticals, Inc $458 29 payments
  9. AstraZeneca Pharmaceuticals LP $448 13 payments
  10. Abbott Laboratories $445 5 payments
  11. Other $2,425 72 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $6,974 5 payments
  2. Food and Beverage $6,922 213 payments
  3. Consulting Fee $3,600 1 payment
  4. Honoraria $3,000 1 payment
  5. Travel and Lodging $1,242 5 payments
  6. Education $70 3 payments
Products named General payments · program years 2019–2025
  1. Repatha $6,754 9 payments
  2. Vascepa $3,606 2 payments
  3. ENTRESTO $712 36 payments
  4. NEXLETOL $609 3 payments
  5. NEXLIZET $609 3 payments
  6. XARELTO $458 29 payments
  7. WATCHMAN FLX $388 7 payments
  8. Impella $325 3 payments
  9. LINQ II $301 5 payments
  10. COREVALVE EVOLUT R $275 5 payments
  11. Other $4,756 137 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 54 drugs

Part D claims

4,612

Median for Internal Medicine: 777

Drug cost

$639,454

Median for Internal Medicine: $73,373

Branded share of claims

18%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 240 $309,103
Xarelto Rivaroxaban Brand 63 $76,759
Entresto Sacubitril/Valsartan Brand 53 $64,231
Multaq Dronedarone Hcl Brand 32 $55,217
Farxiga Dapagliflozin Propanediol Brand 16 $19,535
Repatha Sureclick Evolocumab Brand 21 $19,163
Nexletol Bempedoic Acid Brand 17 $13,751
Ezetimibe Generic 188 $7,155
Ivabradine Hcl Generic 12 $6,900
Atorvastatin Calcium Generic 379 $6,019

The 10 drugs with the highest cost, of 54 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 25 billing codes

Paid by Medicare

$29,655

Medicare's payments for the services billed

Medicare patients

225

Average age 73

Services billed

394

124 women, 101 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Diabetes 37%
Ischemic heart disease 37%
Chronic kidney disease 31%
Depression 25%
Atrial fibrillation 23%
Heart failure 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XARELTO
  • Janssen Pharmaceuticals, Inc $60
$60 63 —
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $33
  • PFIZER INC. $11
$43 240 —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $33
$33 — —
WAINUA
  • AstraZeneca Pharmaceuticals LP $17
$17 — —
Repatha
  • Amgen Inc. $16
$16 21 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

228 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record